Listed by the USPTO as NOLAN, JASON MICHAEL
Tech Center 1600 • Art Units: 1617 1623 1626 1627 1629 1636
This examiner grants 67% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18832840 | HETEROCYCLIC COMPOUNDS | Non-Final OA | Hoffmann-La Roche Inc. |
| 18462918 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Final Rejection | AbbVie Inc. |
| 18962163 | DIETARY TRIPROPIONIN SUPPLEMENTATION TO REDUCE ADIPOSITY AND IMPROVE GLUCOSE HOMEOSTASIS | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18033662 | PDE9 INHIBITORS FOR TREATING CARDIAC FAILURE | Final Rejection | Vanderbilt University |
| 18013302 | COMPOUNDS HAVING ANTICANCER ACTIVITY | Non-Final OA | The Trustees of Princeton University |
| 18562587 | HETEROCYCLIC COMPOUNDS AND METHODS OF PREPARATION THEREOF | Final Rejection | The Medical College of Wisconsin Inc. |
| 18970142 | Imidazole Compounds for Organic Light-Emitting Diodes | Non-Final OA | Arizona Board of Regents on behalf of Arizona State University |
| 17788378 | Aqueous Composition | Final Rejection | Rohto Pharmaceutical Co., Ltd. |
| 18858318 | BORON COMPOUNDS, RELATED LIPID PARTICLES, LIPOPLEXES, COMPOSITIONS, METHODS OF USE, AND METHODS OF MAKING | Non-Final OA | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. |
| 18849010 | Crystal form of Vonoprazan pyroglutamate and preparation method therefor | Non-Final OA | HARWAY (WEIFANG) PHARMACEUTICAL TECHNOLOGY CO., LTD |
| 18577644 | LONG-ACTING BREXPIPRAZOLE PREPARATION FOR INJECTION AND PREPARATION METHOD THEREFOR | Non-Final OA | SICHUAN KELUN PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. |
| 18168028 | USE OF ROLUPERIDONE IN PREVENTING RELAPSE IN SCHIZOPHRENIA PATIENTS | Non-Final OA | Minerva Neurosciences, Inc. |
| 18308148 | ENDOGENOUS STABILIZATION OF CANNABINOIDS | Final Rejection | Abstrax Tech Inc. |
| 18248858 | HETEROCYCLIC GLP-1 AGONISTS | Non-Final OA | Gasherbrum Bio, Inc. |
| 17918557 | NOVEL MEDICAL USE OF MDM2 INHIBITORS | Final Rejection | ASCENTAGE PHARMA GROUP CORP LIMITED |
| 18716804 | NON-TUBERCULOSIS MYCOBACTERIA INFECTION TREATMENT | Non-Final OA | AN2 Therapeutics, Inc. |
| 18562510 | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA, OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH A SOLID FORM OF BITOPERTIN | Non-Final OA | Disc Medicine, Inc. |
| 18712311 | ISOINDOLINES AS PMS2 INHIBITORS | Non-Final OA | NeoPhore Limited |
| 18701664 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Non-Final OA | ARTIOS PHARMA LIMITED |
| 18696916 | NOVEL COMBINATION OF SEROTONIN RECEPTOR (5-HTR2B) ANTAGONIST AND AN IMMUNOMODULATOR AND CHEMOTHERAPEUTIC DRUGS FOR INHIBITION OF CANCER | Non-Final OA | NATIONAL CENTRE FOR CELL SCIENCE |
| 18452054 | Demethylation of Reticuline and Derivatives Thereof with Fungal Cytochrome P450 | Non-Final OA | RIVER STONE BIOTECH, INC. |
| 17996994 | USE OF VEGF INHIBITOR IN PREPARATION OF MEDICAMENT FOR TREATING HYPOXIA-RELATED DISEASES | Non-Final OA | Yihai CAO |
| 18040708 | NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS | Non-Final OA | ITALFARMACO S.P.A. |
| 17922045 | Methods of Use for Single Molecule Compounds Providing Multi-Target Inhibition to Treat Covid 19 | Non-Final OA | SignalRx Pharmaceuticals, Inc. |
| 17779214 | COMBINATION THERAPY USING FABP5 INHIBITORS WITH TAXANES FOR TREATMENT OF CANCER | Non-Final OA | Gregory CARBONETTI |
| 16757759 | METHOD FOR PREPARING HIGH-PURITY TOTAL GINKGOLIDE AND USE THEREOF | Non-Final OA | SPH Xing Ling Sci. & Tech. Pharmaceutical Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy66.6% of resolved applications examined by Jason Michael Nolan were allowed (386 resolved cases), compared with 34.1% across Art Unit 1617 over the last five years.
This examiner's interview lift is -27.2 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Jason Michael Nolan took 999 days on average from filing to allowance.
Jason Michael Nolan examines applications in Art Unit 1617 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
